
Clinical trials in psychiatry rely on measures of symptomatology, not biology. This @ACNPorg position paper lays out why validated biomarkers in psychiatry have lagged behind fields like Alzheimer's and ALS, and what it will take to close the gap: precompetitive data sharing, standardized protocols, & earlier FDA engagement. nature.com/articles/s44277-0…
















